Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tauroursodeoxycholic acid to prevent choledocholithiasis stone recurrence after ERCP
ChiCTR2300071425Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tauroursodeoxycholic acid in choledocholithiasis (2 arms), sponsored by Changhai Hospital. Primary endpoint: Recurrence rate of common bile duct stones at 1 year after ERCP lithotomy. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
choledocholithiasis
Beyond the preview
Go deeper on ChiCTR2300071425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071425.